The impact of personalized medicine has varied based on tumor types and some of the original developments, specifically in genomics and the identification of biomarkers, had a huge impact on breast cancer treatment, Edmund Pezalla, MD, MPH, thinks.
Pezalla believes that personalized medicine has significantly affected outcomes in breast cancer. “With the discovery of HER2, and the identification of HER2-expressing tumors that responded to specific medications has been a big breakthrough and there have been huge improvements in breast cancer because of that and the discovery of other markers,” he said.
In his opinion, we are still in the learning phase for other tumor types, although lung cancer has seen some breakthroughs. A small number of patients who express the right biomarkers for some of the newer oncology drugs on the market are seeing success. “Not cures necessarily, but success in improving [patient] outcomes, their length of life, and their overall survival, because they have been identified as a candidate for that particular drug.”
The impact of personalized medicine, though, has been felt beyond oncology such as in cystic fibrosis, where certain genetic subtypes are treatable so a patient can lead a normal life and maybe even a normal life span, Pezalla said.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
The Senate Finance Committee has introduced bipartisan legislation that proposes using Medicaid and Medicare programs to help prevent and reduce generic drug shortages; US indicators for COVID-19, flu, and respiratory syncytial virus (RSV) declined further last week; findings from a recent study reveal growing disparities in child death rates across racial and ethnic groups.
Read More